Universität zu Köln

Neusser, Silke ORCID: 0000-0001-9077-7005, Lux, Beate, Barth, Cordula, Pahmeier, Kathrin, Rhiem, Kerstin, Schmutzler, Rita, Engel, Christoph ORCID: 0000-0002-7247-282X, Wasem, Jurgen, Huster, Stefan, Dabrock, Peter and Neumann, Anja (2019). The budgetary impact of genetic testing for hereditary breast cancer for the statutory health insurance. Curr. Med. Res. Opin., 35 (12). S. 2103 - 2111. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1473-4877

Full text not available from this repository.

Abstract

Objectives: Potential opportunities and challenges of predictive genetic risk classification of healthy persons are currently discussed. However, the budgetary impact of rising demand is uncertain. This project aims to evaluate budgetary consequences of predictive genetic risk classification for statutory health insurance in Germany. Methods: A Markov model was developed in the form of a cohort simulation. It analyzes a population of female relatives of hereditary breast cancer patients. Mutation carriers are offered intensified screening, women with a BRCA1 or BRCA2 mutation can decide on prophylactic mastectomy and/or ovarectomy. The model considers the following scenarios: (a) steady demand for predictive genetic testing, and (b) rising demand. Most input parameters are based on data of the German Consortium for Hereditary Breast and Ovarian Cancer. The model contains 49 health states, starts in 2015, and runs for 10 years. Prices were evaluated from the perspective of statutory health insurance. Results: Steady demand leads to an expenditure of euro49.8 million during the 10-year period. Rising demands lead to additional expenses of euro125.5 million. The model reveals the genetic analysis to be the main cost driver while cost savings in treatment costs of breast and ovarian cancer are indicated. Conclusions: The results contribute to close the knowledge gap concerning the budgetary consequences due to genetic risk classification. A rising demand leads to additional costs especially due to costs for genetic analysis. The model indicates budget shifts with cost savings due to breast and ovarian cancer treatment in the scenario of rising demands.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Neusser, Silke UNSPECIFIED orcid.org/0000-0001-9077-7005 UNSPECIFIED Lux, Beate UNSPECIFIED UNSPECIFIED UNSPECIFIED Barth, Cordula UNSPECIFIED UNSPECIFIED UNSPECIFIED Pahmeier, Kathrin UNSPECIFIED UNSPECIFIED UNSPECIFIED Rhiem, Kerstin UNSPECIFIED UNSPECIFIED UNSPECIFIED Schmutzler, Rita UNSPECIFIED UNSPECIFIED UNSPECIFIED Engel, Christoph UNSPECIFIED orcid.org/0000-0002-7247-282X UNSPECIFIED Wasem, Jurgen UNSPECIFIED UNSPECIFIED UNSPECIFIED Huster, Stefan UNSPECIFIED UNSPECIFIED UNSPECIFIED Dabrock, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Neumann, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-141638
DOI:	10.1080/03007995.2019.1654689
Journal or Publication Title:	Curr. Med. Res. Opin.
Volume:	35
Number:	12
Page Range:	S. 2103 - 2111
Date:	2019
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1473-4877
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language COST-EFFECTIVENESS; OVARIAN Multiple languages Medicine, General & Internal; Medicine, Research & Experimental Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14163